Demographic, clinical, and laboratory parameters of the juvenile-onset systemic lupus erythematosus patients. by Butsabong Lerkvaleekul (12055191)

Subjects:

Stratification of the juvenile-onset systemic lupus erythematosus patients by the median percentage of each lymphocyte subset. by Butsabong Lerkvaleekul (12055191)

Subjects:

Lymphocyte subset distribution during longitudinal follow-up in JSLE patients. by Butsabong Lerkvaleekul (12055191)

Subjects:

Percentages of lymphocyte subsets in the juvenile-onset systemic lupus erythematosus patients. by Butsabong Lerkvaleekul (12055191)

Subjects:

The number and ASR of deaths for <i>Klebsiella pneumoniae</i>-related LRI burden in 1990 and 2021, and its trends from 1990 to 2021. by Juanjuan Li (399633)

The number and ASR of DALYs for <i>Klebsiella pneumoniae</i>-related LRI burden in 1990 and 2021, and its trends from 1990 to 2021. by Juanjuan Li (399633)

The relative quantitative values of 3 SAP-targeted peptides and 1 PPBP-targeted peptide. by Kumiko Shirai (13014884)

Related inflammation evaluation indexes before and after operation (mean±standard deviation). by Na Wang (193263)

Estimation of relative treatment effects on hospital mortality. by Thunyarat Anothaisintawee (840641)

Estimation of relative treatment effects on disease recurrence (above diagonal line) and drug discontinuation (below diagonal line). by Thunyarat Anothaisintawee (840641)

Decrease in vRNA in brain during antiretroviral therapy. by Sonny R. Elizaldi (9684796)

Estimation of relative treatment effects on adverse drug events. by Thunyarat Anothaisintawee (840641)

Correlation between relative amounts of lipid species and number of days since the onset of symptoms among COVID-19 cases. by Spela Kokelj (8356644)

Subjects:

Effects for statistical significant explanatory variables on the postponement time until the next disease diagnosis. by Nikolaj Normann Holm (15333087)

Excessive LF4A kinase activity shortens cilia and decreases IFT. by Yu-Yang Jiang (7036916)

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

6:2 Chlorinated Polyfluoroalkyl Ether Sulfonate (F-53B) Induces Aging and Parkinson’s Disease-like Disorders in <i>C. elegans</i> at Low Concentrations by Hui Li (32376)

“…After exposure to F-53B at 2, 10, and 50 ng/L, C. elegans showed an aging phenomenon as lipofuscin was significantly increased by 48.7–57.5% and locomotion, such as center point speed, was significantly decreased in all exposure groups. …”

Average cost per visit for HIV and HTN care (absolute vs. relative contributions). by Drew B. Cameron (10687420)